Tremelimumab for Mesothelioma

Tremelimumab is a CTLA-4 immune checkpoint inhibitor that has been studied as a treatment for malignant pleural mesothelioma in several clinical trials. It belongs to the same drug class as ipilimumab (Yervoy) — both block the CTLA-4 protein on T cells, releasing a key brake on the immune system and enhancing the body's ability to mount an anti-tumor response. While tremelimumab has not achieved FDA approval for mesothelioma as a single agent, its combination with durvalumab continues to be investigated and has shown signals of activity.¹

The CTLA-4 pathway is one of the earliest immune checkpoints activated during an immune response. When CTLA-4 on a T cell binds to its ligands (B7 proteins on antigen-presenting cells), it sends an inhibitory signal that prevents the T cell from becoming fully activated. By blocking this interaction, tremelimumab allows T cells to achieve full activation, proliferate, and attack tumor cells more aggressively. This mechanism is complementary to PD-1/PD-L1 inhibition, which operates at a later stage of the immune response within the tumor microenvironment.²

The DETERMINE trial was the largest randomized study of tremelimumab in mesothelioma. This phase IIb, double-blind, placebo-controlled trial enrolled 571 previously treated mesothelioma patients across 101 centers in 19 countries. Unfortunately, tremelimumab monotherapy did not significantly improve overall survival compared to placebo (median OS 7.7 months vs. 7.3 months). However, a subset of patients achieved durable responses lasting more than a year, and exploratory analyses suggested that patients with non-epithelioid histology and inflammatory tumor profiles may derive greater benefit.¹

Despite the negative primary endpoint in DETERMINE, tremelimumab remains relevant in mesothelioma research as a combination partner for durvalumab. The dual checkpoint blockade approach (PD-L1 + CTLA-4 inhibition) mirrors the successful strategy of nivolumab plus ipilimumab, and tremelimumab/durvalumab combinations are being studied in ongoing mesothelioma trials.³

Tremelimumab has been evaluated in several clinical trial settings for mesothelioma:¹

DETERMINE Trial — Single-Agent Tremelimumab

The largest randomized trial of tremelimumab in mesothelioma:¹

• Design — Phase IIb, double-blind, placebo-controlled; 571 patients across 19 countries
• Population — Previously treated (second- or third-line) unresectable malignant pleural mesothelioma
• Dosing — Tremelimumab 10 mg/kg every 4 weeks for 7 doses, then every 12 weeks
• Primary endpoint — Overall survival: not met (7.7 months vs. 7.3 months for placebo; HR 0.92, p=0.41)
• Notable finding — Durable responses observed in a subset of patients; some responses lasted over 2 years

Combination With Durvalumab

Tremelimumab combined with durvalumab (dual checkpoint blockade) is under active investigation:³

• Rationale — CTLA-4 blockade (tremelimumab) enhances T-cell priming and activation, while PD-L1 blockade (durvalumab) prevents tumor-mediated T-cell suppression in the tumor microenvironment
• Parallel — Mirrors the nivolumab + ipilimumab approach that achieved FDA approval for mesothelioma via CheckMate 743
• Dosing — Tremelimumab 300 mg (single dose or limited doses) + durvalumab 1500 mg every 4 weeks

Early-Phase Studies

Earlier single-arm phase II studies of tremelimumab in mesothelioma demonstrated objective response rates of 7–10%, with disease control rates of approximately 31% and evidence of durable benefit in a minority of patients. These results supported the larger DETERMINE trial, and while the phase IIb results were negative overall, they informed the strategy of combining CTLA-4 inhibitors with PD-1/PD-L1 inhibitors.²

As a single agent, tremelimumab showed limited overall benefit in unselected mesothelioma patients, but combination strategies remain promising:¹

• DETERMINE trial — No significant overall survival improvement vs. placebo (median 7.7 vs. 7.3 months)
• Durable responses — Approximately 5% of patients achieved durable responses lasting over one year, highlighting the potential for exceptional benefit in a small subset
• Non-epithelioid benefit — Exploratory analyses suggest patients with sarcomatoid or biphasic histology may derive greater relative benefit from CTLA-4 inhibition
• Combination potential — The nivolumab/ipilimumab experience (CheckMate 743) validates dual checkpoint blockade in mesothelioma; tremelimumab/durvalumab combinations are expected to show similar activity

CTLA-4 inhibitors like tremelimumab tend to cause more immune-related adverse events than PD-1/PD-L1 inhibitors alone, reflecting the broader immune activation they produce:¹

• Diarrhea/colitis — The most common significant side effect, affecting 15–25% of patients at any grade. Immune-mediated colitis can be severe and requires prompt treatment with corticosteroids. Report persistent diarrhea (more than 4 stools per day above baseline) immediately
• Skin reactions — Rash, pruritus (itching), and dermatitis occur in 25–40% of patients. Most are mild and managed with topical treatments, but severe reactions require systemic corticosteroids
• Hepatotoxicity — Immune-mediated liver inflammation occurs in 5–15% of patients. Liver function tests are monitored before every infusion
• Endocrine disorders — Thyroid dysfunction, adrenal insufficiency, and hypophysitis (pituitary inflammation) are less common but may require lifelong hormone replacement
• Fatigue — Affects 20–30% of patients; usually manageable with activity modification and rest
• Combination toxicity — When tremelimumab is combined with durvalumab, the rate of immune-related adverse events increases compared to either drug alone. Close monitoring and early intervention are essential